A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.

Autor:	Tamari R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., McLornan DP; Department of Medicine, University College Hospital, London, United Kingdom., Ahn KW; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., Estrada-Merly N; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., Hernández-Boluda JC; Department of Hematology, Hospital Clínico Universitario, Valencia, Spain., Giralt S; Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Palmer J; Department of Medicine, Mayo Clinic Arizona and Phoenix Children's Hospital, Phoenix, AZ., Gale RP; Department of Immunology and Inflammation, Haematology Centre, Imperial College London, London, United Kingdom., DeFilipp Z; Department of Medicine, Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA., Marks DI; Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom., van der Poel M; Division of Hematology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., Verdonck LF; Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands., Battiwalla M; Outcomes Research, Sarah Cannon Blood Cancer Network, Nashville, TN., Diaz MA; Department of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain., Gupta V; Department of Internal Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada., Ali H; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Litzow MR; Division of Hematology and Transplant Center, Mayo Clinic, Rochester, MN., Lazarus HM; Department of Hematology and Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH., Gergis U; Division of Hematological Malignancies, Department of Medicine Oncology, Thomas Jefferson University, Philadelphia, PA., Bashey A; Department of Medicine, Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA., Liesveld J; Department of Medicine, University of Rochester Medical Center, Rochester, NY., Hashmi S; Department of Internal Medicine, Mayo Clinic, Rochester, MN.; Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates., Pu JJ; Department of Medicine, Banner University Medical Center Tucson, Syracuse, NY., Beitinjaneh A; Divison of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL., Bredeson C; Department of Medicine, The Ottawa Hospital Transplant & Cellular Therapy Program, Ottawa, ON, Canada., Rizzieri D; Novant Health Cancer Institute, Winston Salem, NC., Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Abid MB; Divisions of Hematology/Oncology & Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Ganguly S; Department of Medicine, Houston Methodist Hospital and Cancer Center, Houston, TX., Agrawal V; Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Ulrike Bacher V; Department of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Wirk B; Department of Medicine, Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, PA., Jain T; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Cutler C; Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA., Aljurf M; Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia., Kindwall-Keller T; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA., Kharfan-Dabaja MA; Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL., Hildebrandt GC; Division of Hematology, Markey Cancer Center, University of Kentucky, Lexington, KY., Pawarode A; Division of Hematology/Oncology, Department of Internal Medicine, Blood and Marrow Transplantation Program, University of Michigan Medical School, Ann Arbor, MI., Solh MM; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA., Yared JA; Division of Hematology/Oncology, Department of Medicine, Transplantation & Cellular Therapy Program, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD., Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Nathan S; Department of Internal Medicine, Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL., Nishihori T; Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL., Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan., Scott BL; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Nakamura R; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Oran B; Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX., Czerw T; Department of Haematology and BMT, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Yakoub-Agha I; Department of Hematology, CHRU Hopital Claude Huriez, Lille, France., Saber W; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2023 Aug 08; Vol. 7 (15), pp. 3993-4002.
DOI:	10.1182/bloodadvances.2023009886
Abstrakt:	To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the Center for International Blood and Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients who received transplantation in Europe (the European Bone Marrow Transplant [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98-1.96), and HLA-matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with an increased hazard of death and were assigned 1 point. Hemoglobin levels <100 g/L at time of transplantation (HR, 1.63; 95% CI, 1.2-2.19) and a mismatched unrelated donor (HR, 1.78; 95% CI, 1.25-2.52) were assigned 2 points. The 3-year overall survival (OS) in patients with a low (1-2 points), intermediate (3-4 points), and high score (5 points) were 69% (95% CI, 61-76), 51% (95% CI, 46-56.4), and 34% (95% CI, 21-49), respectively (P < .001). Increasing score was predictive of increased transplant-related mortality (TRM; P = .0017) but not of relapse (P = .12). The derived score was predictive of OS (P < .001) and TRM (P = .002) but not of relapse (P = .17) in the EBMT cohort as well. The proposed system was prognostic of survival in 2 large cohorts, CIBMTR and EBMT, and can easily be applied by clinicians consulting patients with MF about the transplantation outcomes. (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu